— Obalon Therapeutics (NASDAQ: OBLN) reported a net loss of $0.61 per share for the third quarter of 2019, vs. $2.14 per share loss expected.
— Third-quarter net loss was $3.7 million, compared to a loss of $6.7 million a year earlier
— Revenue decreased to $0.3 million from $3.0 million in the third quarter of 2018, vs. $1.2 million loss expected
— Cost of revenue was $0.4 million, down from $1.4 million in the same period of last year
— Research and development expense declined sharply to $1.2 million from $2.4 million last year
— Opened the first company-owned retail treatment center, the Obalon Center for Weight Loss
— Raised $16.6 million in gross proceeds from an equity offering
— Promoted William Plovanic to President and CEO; promoted Nooshin Hussainy to CFO
Most Popular
Infographic: How Alaska Air Group (ALK) performed in Q1 2024
Alaska Air Group (NYSE: ALK) reported its first quarter 2024 earnings results today. Total operating revenue increased 2% year-over-year to $2.23 billion. Net loss amounted to $132 million, or $1.05 per
KMI Earnings: Kinder Morgan Q1 2024 adjusted profit increases; revenue drops
Kinder Morgan, Inc. (NYSE: KMI) reported higher adjusted earnings for the first quarter of 2024 despite a decrease in revenues. The energy infrastructure company also issued guidance for the full
What to expect when Altria (MO) reports first quarter 2024 earnings results
Shares of Altria Group, Inc. (NYSE: MO) stayed green on Wednesday. The stock has dropped 8% over the past one month. The tobacco giant is scheduled to report its first
